

---

**Product Data Sheet**


---

Product Name: Azido-PEG3-Val-Cit-PAB-PNP

Cat. No.: GC60069

**Chemical Properties**

Cas. No. 2055047-18-0

SMILES O=C(N)[C@H](CCCN(C(=O)N)N(C([C@H](C(C)C)NC(COCCOCCOCCN=[N+]=[N-])=O)=O)C1=CC=C(COC(OC2=CC=C([N+])([O-])=O)C=C2)=O)C=C1

Formula C<sub>34</sub>H<sub>47</sub>N<sub>9</sub>O<sub>12</sub>

M.Wt

773.79

Solubility

Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Background**

Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[2].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Dan N, et al. Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications. Pharmaceuticals (Basel). 2018 Apr 9;11(2). pii: E32. [2]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---